Media Mentions
2011
“As Comment Period Ends, FDA Seeks to Clarify Conflict of Interest Rules”
Genetic Engineering & Biotechnology News, July 27, 2011
Jennifer Geetter said that FDA clarification on conflict of interest rules for clinical researchers tied to companies or institutions “should be seen as a floor and not a ceiling.” She urged “a more robust, more deliberate process” in which organizations tell researchers or doctors, “These are the types of financial interests that if you have, you’ll have to disclose. We’ll decide if they’re conflicts of interest, and how they can be managed.”
2010
Jennifer Geetter reviewed for Health Information Compliance Insider (August 2010) how the Department of Health & Human Services Office for Civil Rights will require protection of electronic personal health information (PHI) in accord with the 2009 HITECH Act and with HIPAA requirements. The Act requires de-identifying electronic health records so they are no longer considered PHI, and Ms. Geetter stated that "central to this exercise is high confidence that the remaining information cannot be re-identified and linked to a specific person." She added that de-identification is not simple, because it involves "concerns and questions about when information is really de-identified and how best to balance privacy risks with risks that the information will be rendered useless for other important public priorities, such as research." Click here to read the full article.
Jennifer S. Geetter, Health, HIPAA, HIPAA Privacy Solutions
2009
Jennifer Geetter was quoted by AISHealth.com on May 4 in a story about the Institute of Medicine's new recommended conflict of interest policies governing the relationships between health care institutions and pharmaceutical and medical device companies. "One of the challenges in management [of conflicts of interest] right now is most people recognize that they need to do it, but there are a lot of question marks around the how," Ms. Geetter said. "Now institutions are looking for matches between individual interests, imputed interests and institutional interests," which makes the process more inter-related and complex. She added concerning such relationships, "This is not just a compliance issue – it is a process issue. You [must] have a process in place that is flexible and elegant enough, that can handle all your problems, but is simple and transparent. And it has to be integrated into the other parts of your organization."
Jennifer S. Geetter, Conflicts of Interest - Health, Health
2008
Jennifer Geetter, Robert Nicholas and Paul Radensky had their On the Subject published in the May 30 edition of Health Law 360 regarding the FDA Draft Guidance on certification of compliance with the new FDAAA clinical trial registration and posting regime.
Jennifer S. Geetter, Paul W. Radensky M.D., Health, Life Sciences - Health
Jennifer Geetter was quoted in the May 21 issue of Health Law360 in an article regarding the Genetic Information Nondiscrimination Act, which seeks to prevent unauthorized or required genetic testing of workers by employers and insurers. "A majority of insurers will not be affected by the act because they already do not use risk rating procedures based on genetic testing or family history," Ms. Geetter said.
Jennifer S. Geetter, Health, Life Sciences - Health
Stephen W. Bernstein and Jennifer S. Geetter were quoted in the February 1 issue of Mass High Tech in an article regarding the state of Massachusetts funding stem cell research. "States see it as a hot new thing, and that's debatable. But in Massachusetts we have all the raw expertise and can use legislation to springboard what's already here," Mr. Bernstein said. "State programs can clarify legal aspects. It's an opportunity for states to clear up any state regulations which may impede stem cell research. State privacy laws are a patchwork, and you can get tangled in ways the legislation didn't intend," Ms. Geetter said.
Stephen W. Bernstein, Jennifer S. Geetter, Health, Life Sciences & Medical Products, Life Sciences - Health
2005
Daniel Curto, Jennifer Geetter, Laura McLane and Amanda J. Metts have been named Rising Stars by Super Lawyers. This list features the results of a poll determining the most highly recognized lawyers under the age of 40 and was published in the May issue of Boston Magazine.
Daniel A. Curto, Jennifer S. Geetter, Laura McLane, Amanda J. Metts
